Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: A randomised, double-blind, placebo-controlled trial

K. Zaman, Dang Duc Anh, John C. Victor, Sunheang Shin, Md Yunus, Michael J. Dallas, Goutam Podder, Vu Dinh Thiem, Le Thi Phuong Mai, Stephen P. Luby, Le Huu Tho, Michele L. Coia, Kristen Lewis, Stephen B. Rivers, David Allen Sack, Florian Schödel, A. Duncan Steele, Kathleen M. Neuzil, Max Ciarlet

Research output: Contribution to journalArticle

Abstract

Background: Rotavirus vaccine has proved effective for prevention of severe rotavirus gastroenteritis in infants in developed countries, but no efficacy studies have been done in developing countries in Asia. We assessed the clinical efficacy of live oral pentavalent rotavirus vaccine for prevention of severe rotavirus gastroenteritis in infants in Bangladesh and Vietnam. Methods: In this multicentre, double-blind, placebo-controlled trial, undertaken in rural Matlab, Bangladesh, and urban and periurban Nha Trang, Vietnam, infants aged 4-12 weeks without symptoms of gastrointestinal disorders were randomly assigned (1:1) to receive three oral doses of pentavalent rotavirus vaccine 2 mL or placebo at around 6 weeks, 10 weeks, and 14 weeks of age, in conjunction with routine infant vaccines including oral poliovirus vaccine. Randomisation was done by computer-generated randomisation sequence in blocks of six. Episodes of gastroenteritis in infants who presented to study medical facilities were reported by clinical staff and from parent recollection. The primary endpoint was severe rotavirus gastroenteritis (Vesikari score ≥11) arising 14 days or more after the third dose of placebo or vaccine to end of study (March 31, 2009; around 21 months of age). Analysis was per protocol; infants who received scheduled doses of vaccine or placebo without intervening laboratory-confirmed naturally occurring rotavirus disease earlier than 14 days after the third dose and had complete clinical and laboratory results were included in the analysis. This study is registered with ClinicalTrials.gov, number NCT00362648. Findings: 2036 infants were randomly assigned to receive pentavalent rotavirus vaccine (n=1018) or placebo (n=1018). 991 infants assigned to pentavalent rotavirus vaccine and 978 assigned to placebo were included in the per-protocol analysis. Median follow up from 14 days after the third dose of placebo or vaccine until final disposition was 498 days (IQR 480-575). 38 cases of severe rotavirus gastroenteritis (Vesikari score ≥11) were reported during more than 1197 person-years of follow up in the vaccine group, compared with 71 cases in more than 1156 person years in the placebo group, resulting in a vaccine efficacy of 48·3 (95 CI 22·3-66·1) against severe disease (p=0·0005 for efficacy >0) during nearly 2 years of follow-up. 25 (2·5) of 1017 infants assigned to receive vaccine and 20 (2·0) of 1018 assigned to receive placebo had a serious adverse event within 14 days of any dose. The most frequent serious adverse event was pneumonia (vaccine 12 [1·2]; placebo 15 [1·5]). Interpretation: In infants in developing countries in Asia, pentavalent rotavirus vaccine is safe and efficacious against severe rotavirus gastroenteritis, and our results support expanded WHO recommendations to promote its global use.

Original languageEnglish (US)
Pages (from-to)615-623
Number of pages9
JournalThe Lancet
Volume376
Issue number9741
DOIs
StatePublished - Aug 2010

Fingerprint

Rotavirus Vaccines
Rotavirus
Gastroenteritis
Developing Countries
Placebos
Vaccines
Bangladesh
Vietnam
Random Allocation
Oral Poliovirus Vaccine
Developed Countries
Pneumonia

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia : A randomised, double-blind, placebo-controlled trial. / Zaman, K.; Anh, Dang Duc; Victor, John C.; Shin, Sunheang; Yunus, Md; Dallas, Michael J.; Podder, Goutam; Thiem, Vu Dinh; Mai, Le Thi Phuong; Luby, Stephen P.; Tho, Le Huu; Coia, Michele L.; Lewis, Kristen; Rivers, Stephen B.; Sack, David Allen; Schödel, Florian; Steele, A. Duncan; Neuzil, Kathleen M.; Ciarlet, Max.

In: The Lancet, Vol. 376, No. 9741, 08.2010, p. 615-623.

Research output: Contribution to journalArticle

Zaman, K, Anh, DD, Victor, JC, Shin, S, Yunus, M, Dallas, MJ, Podder, G, Thiem, VD, Mai, LTP, Luby, SP, Tho, LH, Coia, ML, Lewis, K, Rivers, SB, Sack, DA, Schödel, F, Steele, AD, Neuzil, KM & Ciarlet, M 2010, 'Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: A randomised, double-blind, placebo-controlled trial', The Lancet, vol. 376, no. 9741, pp. 615-623. https://doi.org/10.1016/S0140-6736(10)60755-6
Zaman, K. ; Anh, Dang Duc ; Victor, John C. ; Shin, Sunheang ; Yunus, Md ; Dallas, Michael J. ; Podder, Goutam ; Thiem, Vu Dinh ; Mai, Le Thi Phuong ; Luby, Stephen P. ; Tho, Le Huu ; Coia, Michele L. ; Lewis, Kristen ; Rivers, Stephen B. ; Sack, David Allen ; Schödel, Florian ; Steele, A. Duncan ; Neuzil, Kathleen M. ; Ciarlet, Max. / Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia : A randomised, double-blind, placebo-controlled trial. In: The Lancet. 2010 ; Vol. 376, No. 9741. pp. 615-623.
@article{e979b93f623b45f4a3fce75578569857,
title = "Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: A randomised, double-blind, placebo-controlled trial",
abstract = "Background: Rotavirus vaccine has proved effective for prevention of severe rotavirus gastroenteritis in infants in developed countries, but no efficacy studies have been done in developing countries in Asia. We assessed the clinical efficacy of live oral pentavalent rotavirus vaccine for prevention of severe rotavirus gastroenteritis in infants in Bangladesh and Vietnam. Methods: In this multicentre, double-blind, placebo-controlled trial, undertaken in rural Matlab, Bangladesh, and urban and periurban Nha Trang, Vietnam, infants aged 4-12 weeks without symptoms of gastrointestinal disorders were randomly assigned (1:1) to receive three oral doses of pentavalent rotavirus vaccine 2 mL or placebo at around 6 weeks, 10 weeks, and 14 weeks of age, in conjunction with routine infant vaccines including oral poliovirus vaccine. Randomisation was done by computer-generated randomisation sequence in blocks of six. Episodes of gastroenteritis in infants who presented to study medical facilities were reported by clinical staff and from parent recollection. The primary endpoint was severe rotavirus gastroenteritis (Vesikari score ≥11) arising 14 days or more after the third dose of placebo or vaccine to end of study (March 31, 2009; around 21 months of age). Analysis was per protocol; infants who received scheduled doses of vaccine or placebo without intervening laboratory-confirmed naturally occurring rotavirus disease earlier than 14 days after the third dose and had complete clinical and laboratory results were included in the analysis. This study is registered with ClinicalTrials.gov, number NCT00362648. Findings: 2036 infants were randomly assigned to receive pentavalent rotavirus vaccine (n=1018) or placebo (n=1018). 991 infants assigned to pentavalent rotavirus vaccine and 978 assigned to placebo were included in the per-protocol analysis. Median follow up from 14 days after the third dose of placebo or vaccine until final disposition was 498 days (IQR 480-575). 38 cases of severe rotavirus gastroenteritis (Vesikari score ≥11) were reported during more than 1197 person-years of follow up in the vaccine group, compared with 71 cases in more than 1156 person years in the placebo group, resulting in a vaccine efficacy of 48·3 (95 CI 22·3-66·1) against severe disease (p=0·0005 for efficacy >0) during nearly 2 years of follow-up. 25 (2·5) of 1017 infants assigned to receive vaccine and 20 (2·0) of 1018 assigned to receive placebo had a serious adverse event within 14 days of any dose. The most frequent serious adverse event was pneumonia (vaccine 12 [1·2]; placebo 15 [1·5]). Interpretation: In infants in developing countries in Asia, pentavalent rotavirus vaccine is safe and efficacious against severe rotavirus gastroenteritis, and our results support expanded WHO recommendations to promote its global use.",
author = "K. Zaman and Anh, {Dang Duc} and Victor, {John C.} and Sunheang Shin and Md Yunus and Dallas, {Michael J.} and Goutam Podder and Thiem, {Vu Dinh} and Mai, {Le Thi Phuong} and Luby, {Stephen P.} and Tho, {Le Huu} and Coia, {Michele L.} and Kristen Lewis and Rivers, {Stephen B.} and Sack, {David Allen} and Florian Sch{\"o}del and Steele, {A. Duncan} and Neuzil, {Kathleen M.} and Max Ciarlet",
year = "2010",
month = "8",
doi = "10.1016/S0140-6736(10)60755-6",
language = "English (US)",
volume = "376",
pages = "615--623",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Elsevier Limited",
number = "9741",

}

TY - JOUR

T1 - Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia

T2 - A randomised, double-blind, placebo-controlled trial

AU - Zaman, K.

AU - Anh, Dang Duc

AU - Victor, John C.

AU - Shin, Sunheang

AU - Yunus, Md

AU - Dallas, Michael J.

AU - Podder, Goutam

AU - Thiem, Vu Dinh

AU - Mai, Le Thi Phuong

AU - Luby, Stephen P.

AU - Tho, Le Huu

AU - Coia, Michele L.

AU - Lewis, Kristen

AU - Rivers, Stephen B.

AU - Sack, David Allen

AU - Schödel, Florian

AU - Steele, A. Duncan

AU - Neuzil, Kathleen M.

AU - Ciarlet, Max

PY - 2010/8

Y1 - 2010/8

N2 - Background: Rotavirus vaccine has proved effective for prevention of severe rotavirus gastroenteritis in infants in developed countries, but no efficacy studies have been done in developing countries in Asia. We assessed the clinical efficacy of live oral pentavalent rotavirus vaccine for prevention of severe rotavirus gastroenteritis in infants in Bangladesh and Vietnam. Methods: In this multicentre, double-blind, placebo-controlled trial, undertaken in rural Matlab, Bangladesh, and urban and periurban Nha Trang, Vietnam, infants aged 4-12 weeks without symptoms of gastrointestinal disorders were randomly assigned (1:1) to receive three oral doses of pentavalent rotavirus vaccine 2 mL or placebo at around 6 weeks, 10 weeks, and 14 weeks of age, in conjunction with routine infant vaccines including oral poliovirus vaccine. Randomisation was done by computer-generated randomisation sequence in blocks of six. Episodes of gastroenteritis in infants who presented to study medical facilities were reported by clinical staff and from parent recollection. The primary endpoint was severe rotavirus gastroenteritis (Vesikari score ≥11) arising 14 days or more after the third dose of placebo or vaccine to end of study (March 31, 2009; around 21 months of age). Analysis was per protocol; infants who received scheduled doses of vaccine or placebo without intervening laboratory-confirmed naturally occurring rotavirus disease earlier than 14 days after the third dose and had complete clinical and laboratory results were included in the analysis. This study is registered with ClinicalTrials.gov, number NCT00362648. Findings: 2036 infants were randomly assigned to receive pentavalent rotavirus vaccine (n=1018) or placebo (n=1018). 991 infants assigned to pentavalent rotavirus vaccine and 978 assigned to placebo were included in the per-protocol analysis. Median follow up from 14 days after the third dose of placebo or vaccine until final disposition was 498 days (IQR 480-575). 38 cases of severe rotavirus gastroenteritis (Vesikari score ≥11) were reported during more than 1197 person-years of follow up in the vaccine group, compared with 71 cases in more than 1156 person years in the placebo group, resulting in a vaccine efficacy of 48·3 (95 CI 22·3-66·1) against severe disease (p=0·0005 for efficacy >0) during nearly 2 years of follow-up. 25 (2·5) of 1017 infants assigned to receive vaccine and 20 (2·0) of 1018 assigned to receive placebo had a serious adverse event within 14 days of any dose. The most frequent serious adverse event was pneumonia (vaccine 12 [1·2]; placebo 15 [1·5]). Interpretation: In infants in developing countries in Asia, pentavalent rotavirus vaccine is safe and efficacious against severe rotavirus gastroenteritis, and our results support expanded WHO recommendations to promote its global use.

AB - Background: Rotavirus vaccine has proved effective for prevention of severe rotavirus gastroenteritis in infants in developed countries, but no efficacy studies have been done in developing countries in Asia. We assessed the clinical efficacy of live oral pentavalent rotavirus vaccine for prevention of severe rotavirus gastroenteritis in infants in Bangladesh and Vietnam. Methods: In this multicentre, double-blind, placebo-controlled trial, undertaken in rural Matlab, Bangladesh, and urban and periurban Nha Trang, Vietnam, infants aged 4-12 weeks without symptoms of gastrointestinal disorders were randomly assigned (1:1) to receive three oral doses of pentavalent rotavirus vaccine 2 mL or placebo at around 6 weeks, 10 weeks, and 14 weeks of age, in conjunction with routine infant vaccines including oral poliovirus vaccine. Randomisation was done by computer-generated randomisation sequence in blocks of six. Episodes of gastroenteritis in infants who presented to study medical facilities were reported by clinical staff and from parent recollection. The primary endpoint was severe rotavirus gastroenteritis (Vesikari score ≥11) arising 14 days or more after the third dose of placebo or vaccine to end of study (March 31, 2009; around 21 months of age). Analysis was per protocol; infants who received scheduled doses of vaccine or placebo without intervening laboratory-confirmed naturally occurring rotavirus disease earlier than 14 days after the third dose and had complete clinical and laboratory results were included in the analysis. This study is registered with ClinicalTrials.gov, number NCT00362648. Findings: 2036 infants were randomly assigned to receive pentavalent rotavirus vaccine (n=1018) or placebo (n=1018). 991 infants assigned to pentavalent rotavirus vaccine and 978 assigned to placebo were included in the per-protocol analysis. Median follow up from 14 days after the third dose of placebo or vaccine until final disposition was 498 days (IQR 480-575). 38 cases of severe rotavirus gastroenteritis (Vesikari score ≥11) were reported during more than 1197 person-years of follow up in the vaccine group, compared with 71 cases in more than 1156 person years in the placebo group, resulting in a vaccine efficacy of 48·3 (95 CI 22·3-66·1) against severe disease (p=0·0005 for efficacy >0) during nearly 2 years of follow-up. 25 (2·5) of 1017 infants assigned to receive vaccine and 20 (2·0) of 1018 assigned to receive placebo had a serious adverse event within 14 days of any dose. The most frequent serious adverse event was pneumonia (vaccine 12 [1·2]; placebo 15 [1·5]). Interpretation: In infants in developing countries in Asia, pentavalent rotavirus vaccine is safe and efficacious against severe rotavirus gastroenteritis, and our results support expanded WHO recommendations to promote its global use.

UR - http://www.scopus.com/inward/record.url?scp=77956055765&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956055765&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(10)60755-6

DO - 10.1016/S0140-6736(10)60755-6

M3 - Article

C2 - 20692031

AN - SCOPUS:77956055765

VL - 376

SP - 615

EP - 623

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 9741

ER -